Abstract: Crohn’s disease (CD) is a chronic nonspecific intestinal inflammatory disease with a complex pathogenesis. In recent years, the incidence of pediatric CD has been increasing annually. Compared with adult patients, children with CD experience a faster course of disease, a higher rate of surgical treatment, and a higher risk of long-term complications. With the in-depth understanding of the pathogenesis of CD, novel antibody drugs targeting tumor necrosis factor α (TNF-α), interleukins and integrins have emerged, providing more treatment options for pediatric CD patients. This article summarized the pathophysiological mechanism of CD, and studies on the efficacy and safety of various antibody drugs in children with CD, aiming to provide references for the development of CD treatments and clinical rational drug use in CD pediatric patients.